Skip to search formSkip to main contentSkip to account menu

ranibizumab

Known as: V2, RhuFab, Ranibizumab [Chemical/Ingredient], RhuFab V2 
A second-generation, recombinant humanized IgG1 kappa monoclonal antibody fragment directed against human vascular endothelial growth factor (VEGF… 
National Institutes of Health

Related topics

Related topics

19 relations
0.05 ML ranibizumab 10 MG/ML Injection0.05 ML ranibizumab 10 MG/ML Prefilled Syringe [Lucentis]0.05 ML ranibizumab 6 MG/ML Injection [Lucentis]Angiogenesis Inhibition

Broader (2)

Angiogenesis InhibitorsImmunologic Factors

Narrower (1)

Lucentis

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2016
Review
2016
Vascular endothelial growth factor and diabetic macular edema.
Review
2015
Review
2015
Therapeutic aptamers: developmental potential as anticancer drugs
Aptamers, composed of single-stranded DNA or RNA oligonucleotides that interact with target molecules through a specific three… 
Highly Cited
2013
Highly Cited
2013
ANATOMICAL MEASURES AS PREDICTORS OF VISUAL OUTCOMES IN RANIBIZUMAB-TREATED EYES WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Purpose: To investigate if anatomical characteristics of eyes undergoing ranibizumab therapy were predictive of best-corrected… 
2012
2012
Stroke rates after introduction of vascular endothelial growth factor inhibitors for macular degeneration: a time series analysis.
2011
2011
Drug delivery to the posterior segment of the eye through hydrogel contact lenses
Purpose:  Despite pharmacological advances, delivery of drugs to the posterior segment of the eye remains problematic. We… 
Review
2009
Review
2009
Review of the Ocular Angiogenesis Animal Models
Increasing interest in developing reliable and reproducible models to study angiogenesis has emerged due to recent advances in… 
Highly Cited
2009
Highly Cited
2009
Different properties of VEGF-antagonists: Bevacizumab but not Ranibizumab accumulates in RPE cells
BackgroundVascular endothelial growth factor (VEGF) antagonists are currently the therapy of choice for age-related macular… 
Review
2009
Review
2009
A systematic review on the effect of bevacizumab in exudative age-related macular degeneration
Highly Cited
2009
Highly Cited
2009
Intravitreal ranibizumab (Lucentis®) in the treatment of retinal angiomatous proliferation (RAP)
BackgroundRetinal angiomatous proliferation (RAP) is a distinct variant of neovascular age-related macular degeneration (AMD… 
Review
2007
Review
2007
Intravitreal Ranibizumab and Bevacizumab: A Review of Risk
Ranibizumab (Lucentis®), a recombinant monoclonal antibody, blocks all active forms of vascular endothelial growth factor A and… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)